NEW YORK CITY, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Intellia Therapeutics, Inc. ("Intellia" or "the Company") (NASDAQ:NTLA). Investors who purchased Intellia securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/NTLA.
Investigation Details
On January 9, 2025, Intellia issued a press release "announc[ing] its strategic priorities and key anticipated 2025 milestones". Among other items, Intellia announced that it plans to focus its resources on developing drug candidates NTLA-2002 and nex-z and will discontinue development of NTLA-3001, which will result in the Company cutting around 27% of its workforce. Intellia said that it expects to incur charges of approximately $8 million in the first quarter of 2025 in connection with the restructuring. Intellia further announced the retirement of its Chief Scientific Officer, Laura Sepp-Lorenzino, Ph.D. On this news, Intellia’s stock price fell $1.82 per share, or 15.14%, to close at $10.20 per share on January 10, 2025.
What’s Next?
If you are aware of any facts relating to this investigation or purchased Intellia securities, you can assist this investigation by visiting the firm’s site: bgandg.com/NTLA. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660
There is No Cost to You
We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Attorney advertising. Prior results do not guarantee similar outcomes.
Contact
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com
SOURCE: Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
COMTEX_462059908/2457/2025-01-21T10:01:51